Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000521414 | SCV000620359 | uncertain significance | not provided | 2017-08-28 | criteria provided, single submitter | clinical testing | The R269C variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The variant is observed in 6/8356 (0.07%) alleles from individuals of East Asian background in the ExAC dataset (Lek et al., 2016). R269C is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. However, this substitution occurs at a position that is not conserved, and in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. In summary, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
Labcorp Genetics |
RCV000797605 | SCV000937172 | likely benign | Immunodeficiency 35 | 2024-07-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003258850 | SCV003972871 | uncertain significance | Inborn genetic diseases | 2023-05-17 | criteria provided, single submitter | clinical testing | The c.805C>T (p.R269C) alteration is located in exon 7 (coding exon 5) of the TYK2 gene. This alteration results from a C to T substitution at nucleotide position 805, causing the arginine (R) at amino acid position 269 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV000521414 | SCV005192569 | uncertain significance | not provided | criteria provided, single submitter | not provided |